- Home
- HCWB vs AEON Comparison
HCWB vs AEON Comparison
Compare HCWB & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- AEON
- Stock Information
- Founded
- HCWB 2018
- AEON N/A
- Country
- HCWB United States
- AEON United States
- Employees
- HCWB N/A
- AEON N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- HCWB Health Care
- AEON Health Care
- Exchange
- HCWB Nasdaq
- AEON Nasdaq
- Market Cap
- HCWB 8.7M
- AEON 8.0M
- IPO Year
- HCWB 2021
- AEON N/A
- Fundamental
- Price
- HCWB $4.00
- AEON $0.94
- Analyst Decision
- HCWB Strong Buy
- AEON Strong Buy
- Analyst Count
- HCWB 1
- AEON 1
- Target Price
- HCWB $35.00
- AEON $360.00
- AVG Volume (30 Days)
- HCWB 1.3M
- AEON 128.8K
- Earning Date
- HCWB 11-13-2025
- AEON 11-12-2025
- Dividend Yield
- HCWB N/A
- AEON N/A
- EPS Growth
- HCWB N/A
- AEON N/A
- EPS
- HCWB N/A
- AEON N/A
- Revenue
- HCWB $832,841.00
- AEON N/A
- Revenue This Year
- HCWB $178.64
- AEON N/A
- Revenue Next Year
- HCWB N/A
- AEON N/A
- P/E Ratio
- HCWB N/A
- AEON N/A
- Revenue Growth
- HCWB N/A
- AEON N/A
- 52 Week Low
- HCWB $2.77
- AEON $0.38
- 52 Week High
- HCWB $100.80
- AEON $115.57
- Technical
- Relative Strength Index (RSI)
- HCWB 47.15
- AEON 72.13
- Support Level
- HCWB $3.66
- AEON $0.78
- Resistance Level
- HCWB $4.13
- AEON $0.85
- Average True Range (ATR)
- HCWB 0.21
- AEON 0.05
- MACD
- HCWB 0.00
- AEON 0.01
- Stochastic Oscillator
- HCWB 34.60
- AEON 95.39
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.